Original article
Artificial intelligence-assisted identification and retrieval of chronic hepatitis C patients lost to follow-up in the health area of Pontevedra and O Salnés (Spain)
Identificación y recuperación asistida por inteligencia artificial de pacientes con hepatitis C crónica con pérdida de seguimiento en el área sanitaria de Pontevedra y O Salnés (España)
Pablo Parada Vázqueza,◊, Santiago Pérez-Cachafeirob,c,◊, Belén Castiñeira Domíngueza, Juan Manuel González-Pérezd, José Manuel Mera Calviñoa, Raquel Souto-Rodrígueza, Yolanda Falagán Cachafeiroa, Indhira Pérez-Medranoa, Nuria Vázquez-Tempranoe, Matilde Trigof, Alba Carrodeguasg, José Luis González-Sánchezg, Carmen Durán-Parrondoh, Juan Turnesa,
Corresponding author
a Servicio de Aparato Digestivo del Complejo Hospitalario Universitario de Pontevedra/Instituto de Investigación Sanitaria Galicia Sur, Pontevedra, Spain
b Department of Preventive Medicine and Public Health, University of Santiago de Compostela, Santiago de Compostela, Spain
c Admission Service, Complejo Hospitalario Universitario A Coruna, Coruna, Spain
d Subdirección Xeral de Sistemas e Tecnoloxías de Información, Consellería de Sanidade, Xunta de Galicia, Spain
e Unidad de Procesos Infecciosos, Complejo Hospitalario Universitario de Pontevedra, Spain
f Servicio de Microbiología, Complejo Hospitalario Universitario de Pontevedra, Spain
g Gilead Sciences, Spain
h Dirección Xeral de Saude Pública, Consellería de Sanidade, Xunta de Galicia, Spain
Read
717
Timeswas read the article
160
Total PDF
557
Total HTML
Share statistics
array:22 [ "pii" => "S0210570524002085" "issn" => "02105705" "doi" => "10.1016/j.gastrohep.2024.502226" "estado" => "S200" "fechaPublicacion" => "2024-08-14" "aid" => "502226" "copyright" => "The Authors" "copyrightAnyo" => "2024" "documento" => "article" "crossmark" => 0 "subdocumento" => "fla" "abierto" => array:3 [ "ES" => false "ES2" => false "LATM" => false ] "gratuito" => false "lecturas" => array:1 [ "total" => 0 ] "itemSiguiente" => array:17 [ "pii" => "S0210570524002188" "issn" => "02105705" "doi" => "10.1016/j.gastrohep.2024.502235" "estado" => "S200" "fechaPublicacion" => "2024-08-19" "aid" => "502235" "copyright" => "Elsevier España, S.L.U." "documento" => "article" "crossmark" => 0 "subdocumento" => "fla" "abierto" => array:3 [ "ES" => false "ES2" => false "LATM" => false ] "gratuito" => false "lecturas" => array:1 [ "total" => 0 ] "en" => array:11 [ "idiomaDefecto" => true "cabecera" => "<span class="elsevierStyleTextfn">Original article</span>" "titulo" => "Small bowel Crohn's disease: Proximal lesions linked to increased inflammation and biologic treatment needs" "tienePdf" => "en" "tieneTextoCompleto" => "en" "tieneResumen" => array:2 [ 0 => "en" 1 => "es" ] "titulosAlternativos" => array:1 [ "es" => array:1 [ "titulo" => "Enfermedad de Crohn del intestino delgado: Lesiones proximales asociadas a mayor inflamación y necesidad de tratamiento biológico" ] ] "contieneResumen" => array:2 [ "en" => true "es" => true ] "contieneTextoCompleto" => array:1 [ "en" => true ] "contienePdf" => array:1 [ "en" => true ] "autores" => array:1 [ 0 => array:2 [ "autoresLista" => "João Carlos Gonçalves, Cátia Arieira, Sofia Xavier, Joana Magalhães, Maria João Moreira, Bruno Rosa, José Cotter" "autores" => array:7 [ 0 => array:2 [ "nombre" => "João Carlos" "apellidos" => "Gonçalves" ] 1 => array:2 [ "nombre" => "Cátia" "apellidos" => "Arieira" ] 2 => array:2 [ "nombre" => "Sofia" "apellidos" => "Xavier" ] 3 => array:2 [ "nombre" => "Joana" "apellidos" => "Magalhães" ] 4 => array:2 [ "nombre" => "Maria João" "apellidos" => "Moreira" ] 5 => array:2 [ "nombre" => "Bruno" "apellidos" => "Rosa" ] 6 => array:2 [ "nombre" => "José" "apellidos" => "Cotter" ] ] ] ] ] "idiomaDefecto" => "en" "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S0210570524002188?idApp=UINPBA00004N" "url" => "/02105705/unassign/S0210570524002188/v1_202408190401/en/main.assets" ] "itemAnterior" => array:17 [ "pii" => "S0210570520302533" "issn" => "02105705" "doi" => "10.1016/j.gastrohep.2020.05.020" "estado" => "S200" "fechaPublicacion" => "2020-09-04" "aid" => "1593" "copyright" => "Elsevier España, S.L.U." "documento" => "simple-article" "crossmark" => 0 "subdocumento" => "ret" "abierto" => array:3 [ "ES" => false "ES2" => false "LATM" => false ] "gratuito" => false "lecturas" => array:1 [ "total" => 0 ] "en" => array:8 [ "idiomaDefecto" => true "titulo" => "WITHDRAWN: Higher appendicular skeletal muscle mass percentage is an independent protective factor for non-alcoholic steatohepatitis and significant fibrosis in male with NAFLD" "tienePdf" => "en" "tieneTextoCompleto" => 0 "tieneResumen" => "en" "contieneResumen" => array:1 [ "en" => true ] "contienePdf" => array:1 [ "en" => true ] "autores" => array:1 [ 0 => array:2 [ "autoresLista" => "Yilun Xu, Yaqi Guan, Wenyi Jin, Li Ding, Jinming Wu" "autores" => array:5 [ 0 => array:2 [ "nombre" => "Yilun" "apellidos" => "Xu" ] 1 => array:2 [ "nombre" => "Yaqi" "apellidos" => "Guan" ] 2 => array:2 [ "nombre" => "Wenyi" "apellidos" => "Jin" ] 3 => array:2 [ "nombre" => "Li" "apellidos" => "Ding" ] 4 => array:2 [ "nombre" => "Jinming" "apellidos" => "Wu" ] ] ] ] ] "idiomaDefecto" => "en" "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S0210570520302533?idApp=UINPBA00004N" "url" => "/02105705/unassign/S0210570520302533/v2_202101310608/en/main.assets" ] "en" => array:20 [ "idiomaDefecto" => true "cabecera" => "<span class="elsevierStyleTextfn">Original article</span>" "titulo" => "Artificial intelligence-assisted identification and retrieval of chronic hepatitis C patients lost to follow-up in the health area of Pontevedra and O Salnés (Spain)" "tieneTextoCompleto" => true "autores" => array:1 [ 0 => array:4 [ "autoresLista" => "Pablo Parada Vázquez, Santiago Pérez-Cachafeiro, Belén Castiñeira Domínguez, Juan Manuel González-Pérez, José Manuel Mera Calviño, Raquel Souto-Rodríguez, Yolanda Falagán Cachafeiro, Indhira Pérez-Medrano, Nuria Vázquez-Temprano, Matilde Trigo, Alba Carrodeguas, José Luis González-Sánchez, Carmen Durán-Parrondo, Juan Turnes" "autores" => array:14 [ 0 => array:3 [ "nombre" => "Pablo" "apellidos" => "Parada Vázquez" "referencia" => array:2 [ 0 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">a</span>" "identificador" => "aff0005" ] 1 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">◊</span>" "identificador" => "fn0005" ] ] ] 1 => array:3 [ "nombre" => "Santiago" "apellidos" => "Pérez-Cachafeiro" "referencia" => array:3 [ 0 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">b</span>" "identificador" => "aff0010" ] 1 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">c</span>" "identificador" => "aff0015" ] 2 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">◊</span>" "identificador" => "fn0005" ] ] ] 2 => array:3 [ "nombre" => "Belén" "apellidos" => "Castiñeira Domínguez" "referencia" => array:1 [ 0 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">a</span>" "identificador" => "aff0005" ] ] ] 3 => array:3 [ "nombre" => "Juan Manuel" "apellidos" => "González-Pérez" "referencia" => array:1 [ 0 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">d</span>" "identificador" => "aff0020" ] ] ] 4 => array:3 [ "nombre" => "José Manuel" "apellidos" => "Mera Calviño" "referencia" => array:1 [ 0 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">a</span>" "identificador" => "aff0005" ] ] ] 5 => array:3 [ "nombre" => "Raquel" "apellidos" => "Souto-Rodríguez" "referencia" => array:1 [ 0 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">a</span>" "identificador" => "aff0005" ] ] ] 6 => array:3 [ "nombre" => "Yolanda" "apellidos" => "Falagán Cachafeiro" "referencia" => array:1 [ 0 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">a</span>" "identificador" => "aff0005" ] ] ] 7 => array:3 [ "nombre" => "Indhira" "apellidos" => "Pérez-Medrano" "referencia" => array:1 [ 0 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">a</span>" "identificador" => "aff0005" ] ] ] 8 => array:3 [ "nombre" => "Nuria" "apellidos" => "Vázquez-Temprano" "referencia" => array:1 [ 0 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">e</span>" "identificador" => "aff0025" ] ] ] 9 => array:3 [ "nombre" => "Matilde" "apellidos" => "Trigo" "referencia" => array:1 [ 0 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">f</span>" "identificador" => "aff0030" ] ] ] 10 => array:3 [ "nombre" => "Alba" "apellidos" => "Carrodeguas" "referencia" => array:1 [ 0 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">g</span>" "identificador" => "aff0035" ] ] ] 11 => array:3 [ "nombre" => "José Luis" "apellidos" => "González-Sánchez" "referencia" => array:1 [ 0 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">g</span>" "identificador" => "aff0035" ] ] ] 12 => array:3 [ "nombre" => "Carmen" "apellidos" => "Durán-Parrondo" "referencia" => array:1 [ 0 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">h</span>" "identificador" => "aff0040" ] ] ] 13 => array:4 [ "nombre" => "Juan" "apellidos" => "Turnes" "email" => array:1 [ 0 => "jturnesv@gmail.com" ] "referencia" => array:2 [ 0 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">a</span>" "identificador" => "aff0005" ] 1 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">*</span>" "identificador" => "cor0005" ] ] ] ] "afiliaciones" => array:8 [ 0 => array:3 [ "entidad" => "Servicio de Aparato Digestivo del Complejo Hospitalario Universitario de Pontevedra/Instituto de Investigación Sanitaria Galicia Sur, Pontevedra, Spain" "etiqueta" => "a" "identificador" => "aff0005" ] 1 => array:3 [ "entidad" => "Department of Preventive Medicine and Public Health, University of Santiago de Compostela, Santiago de Compostela, Spain" "etiqueta" => "b" "identificador" => "aff0010" ] 2 => array:3 [ "entidad" => "Admission Service, Complejo Hospitalario Universitario A Coruna, Coruna, Spain" "etiqueta" => "c" "identificador" => "aff0015" ] 3 => array:3 [ "entidad" => "Subdirección Xeral de Sistemas e Tecnoloxías de Información, Consellería de Sanidade, Xunta de Galicia, Spain" "etiqueta" => "d" "identificador" => "aff0020" ] 4 => array:3 [ "entidad" => "Unidad de Procesos Infecciosos, Complejo Hospitalario Universitario de Pontevedra, Spain" "etiqueta" => "e" "identificador" => "aff0025" ] 5 => array:3 [ "entidad" => "Servicio de Microbiología, Complejo Hospitalario Universitario de Pontevedra, Spain" "etiqueta" => "f" "identificador" => "aff0030" ] 6 => array:3 [ "entidad" => "Gilead Sciences, Spain" "etiqueta" => "g" "identificador" => "aff0035" ] 7 => array:3 [ "entidad" => "Dirección Xeral de Saude Pública, Consellería de Sanidade, Xunta de Galicia, Spain" "etiqueta" => "h" "identificador" => "aff0040" ] ] "correspondencia" => array:1 [ 0 => array:3 [ "identificador" => "cor0005" "etiqueta" => "⁎" "correspondencia" => "Corresponding author." ] ] ] ] "titulosAlternativos" => array:1 [ "es" => array:1 [ "titulo" => "Identificación y recuperación asistida por inteligencia artificial de pacientes con hepatitis C crónica con pérdida de seguimiento en el área sanitaria de Pontevedra y O Salnés (España)" ] ] "resumenGrafico" => array:2 [ "original" => 1 "multimedia" => array:5 [ "identificador" => "fig0015" "tipo" => "MULTIMEDIAFIGURA" "mostrarFloat" => false "mostrarDisplay" => true "figura" => array:1 [ 0 => array:4 [ "imagen" => "fx1.jpeg" "Alto" => 725 "Ancho" => 1333 "Tamanyo" => 136239 ] ] ] ] "textoCompleto" => "<span class="elsevierStyleSections"><span id="sec0005" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0060">Introduction</span><p id="par0005" class="elsevierStylePara elsevierViewall">Despite the advances made in recent years, the hepatitis C virus (HCV) continues to be a global health problem. According to data from the World Health Organisation (WHO), an estimated 58 million patients have chronic HCV infection worldwide, representing 0.75% of the global population.<a class="elsevierStyleCrossRef" href="#bib0120"><span class="elsevierStyleSup">1</span></a> For this reason, the WHO has recently set the target of HCV elimination by 2030,<a class="elsevierStyleCrossRef" href="#bib0125"><span class="elsevierStyleSup">2</span></a> defined as an annual HCV incidence of ≤5 per 100,000 people not considered at risk and ≤2 per 100 persons who inject or who have ever injected drugs (PWID) and a reduction of HCV-related mortality to ≤2 per 100,000 people.<a class="elsevierStyleCrossRef" href="#bib0125"><span class="elsevierStyleSup">2</span></a></p><p id="par0010" class="elsevierStylePara elsevierViewall">In Spain, important advances in HCV elimination have been made through the National Strategic Plan for the Approach to Hepatitis C (PEACH).<a class="elsevierStyleCrossRef" href="#bib0130"><span class="elsevierStyleSup">3</span></a> More than 135,000 people received HCV treatment between 2015 and 2019, placing Spain in an ideal position to achieve the WHO objectives. However, despite this progress, a 2019 seroprevalence study by the Spanish Ministry of Health indicated that 0.22% of the adult population between 20 and 80 years have active HCV infection.<a class="elsevierStyleCrossRef" href="#bib0135"><span class="elsevierStyleSup">4</span></a> Therefore, according to these percentages, there are over 75,000 people with HCV in Spain. It is estimated that 29.4% of this population have not yet been diagnosed.<a class="elsevierStyleCrossRef" href="#bib0135"><span class="elsevierStyleSup">4</span></a></p><p id="par0015" class="elsevierStylePara elsevierViewall">To achieve the WHO objectives, the latest guidelines from the Spanish Ministry of Health encourage the active search for patients previously diagnosed with HCV but not treated.<a class="elsevierStyleCrossRef" href="#bib0140"><span class="elsevierStyleSup">5</span></a> These guidelines are based on recommendations from the Spanish Association for the Study of the Liver (AEEH).<a class="elsevierStyleCrossRef" href="#bib0145"><span class="elsevierStyleSup">6</span></a> Untreated patients with active HCV infection could be found among: (1) people with a positive antibody test that was not subsequently confirmed by RNA diagnosis of active HCV infection; (2) patients with confirmed viraemia but lost to medical follow-up; or (3) individuals who never received treatment with direct-acting antivirals (DAAs). The exact number of patients from each group is unknown today,<a class="elsevierStyleCrossRef" href="#bib0135"><span class="elsevierStyleSup">4</span></a> but people with diagnosed viraemia would be the most accessible for early identification and treatment.</p><p id="par0020" class="elsevierStylePara elsevierViewall">Several projects have been carried out to actively search for and engage with HCV infected patients, demonstrating the ability to recover a significant proportion of these patients and provide them with appropriate care and follow-up.<a class="elsevierStyleCrossRef" href="#bib0150"><span class="elsevierStyleSup">7</span></a> At the European level, important regional studies have been performed in the Netherlands.<a class="elsevierStyleCrossRefs" href="#bib0155"><span class="elsevierStyleSup">8–10</span></a> In these studies, between 56% and 89% of individuals previously diagnosed with HCV were confirmed to still be actively infected at subsequent evaluations. In Spain, similar projects have also been carried out in different autonomous communities,<a class="elsevierStyleCrossRefs" href="#bib0170"><span class="elsevierStyleSup">11,12</span></a> confirming active infection in 28–63% of patients lost to follow-up. Since most patients are candidates to receive treatment, retrieval and relinkage strategies can significantly contribute to achieving the WHO objectives by way of micro-elimination campaigns at the regional level.<a class="elsevierStyleCrossRef" href="#bib0150"><span class="elsevierStyleSup">7</span></a> In the case of Galicia, despite the higher prevalence of HCV compared to other Spanish regions (mainly due to an high number of PWID in the past),<a class="elsevierStyleCrossRef" href="#bib0180"><span class="elsevierStyleSup">13</span></a> there are no initiatives for the identification and recovery of patients with HCV in this autonomous community to date.</p><p id="par0025" class="elsevierStylePara elsevierViewall">The aim of this study was to identify and retrieve patients diagnosed with chronic HCV who were lost to follow-up in our health area and reincorporate them into the health system. Artificial intelligence technology facilitated a more effective and accurate identification of these patients. In addition to the possibility of offering them treatment, this type of project generates first-hand knowledge of the reasons behind loss to follow-up and the specific deficiencies in the HCV care pathway where the loss occurred.<a class="elsevierStyleCrossRef" href="#bib0185"><span class="elsevierStyleSup">14</span></a> Some patients were never referred to a specialist doctor, while others were lost to medical follow-up at later stages.<a class="elsevierStyleCrossRef" href="#bib0150"><span class="elsevierStyleSup">7</span></a> Pinpointing the weak points of the chain and the reasons for loss to follow-up will help optimise HCV elimination programmes.</p></span><span id="sec0010" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0065">Material and methods</span><span id="sec0015" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0070">Study design, patient identification and retrieval</span><p id="par0030" class="elsevierStylePara elsevierViewall">The study covered the population in the health area of Pontevedra and O Salnés (approximately 300,000 people) between 2007 and 2019. We conducted an active retrospective search of previously diagnosed HCV cases recorded in the Galician Health Service (SERGAS) proprietary health information exchange database (IANUS) using the HEXIN application (Herramientas para la EXplotación de la INformación). This software employs big data and artificial intelligence technologies for the analysis of clinical history data of microbiology, pharmacy and drug addiction units. The software was trained to identify patients with HCV who had been lost to follow-up, and algorithms were generated to select these patients according to the information contained in the clinical records of our health area.</p><p id="par0035" class="elsevierStylePara elsevierViewall">Medical histories of patients identified were reviewed and analysed by the authors of the study. The following groups were excluded: (1) patients discontinued from HCV treatment after the introduction of DAAs for medical reasons, such as advanced age, comorbidities or palliative care; (2) patients treated in other health areas or in clinical trials; (3) patients in active clinical follow-up by gastroenterology or infectious diseases departments at our centre or in other health areas; (4) patients currently receiving treatment or pending confirmation of sustained virological response (SVR); and (5) patients with HIV coinfection, who were referred to the infectious diseases department of our hospital. The remaining cases were classified as patients with chronic HCV infection who had since been lost to follow-up in our health area and designated as candidates for DAA treatment by the gastroenterology department.</p><p id="par0040" class="elsevierStylePara elsevierViewall">Patients were further categorised as having been lost to follow-up care after attending a first visit with a gastroenterologist or as having never been referred or linked to care post-diagnosis. The first group were contacted by telephone by a gastroenterologist or nurse, informing them of the situation and offering a new consultation appointment. For the second group, the respective primary care physician was notified and asked to refer the patient to the gastroenterology department.</p><p id="par0045" class="elsevierStylePara elsevierViewall">For the retrieved patients, an initial evaluation was conducted to determine their eligibility for antiviral treatment. The decision to initiate treatment was based on current clinical practice. Follow-up care included regular monitoring to assess the efficacy of the treatment and manage any adverse effects, aiming for a sustained virological response (SVR). SVR was defined as undetectable HCV RNA determined by using Cobas Ampliprep Cobas TaqMan HCV 2.0/Cobas 6800 (Roche Diagnostics) real-time polymerase chain reaction-based assays assessed 12 weeks after treatment.</p></span><span id="sec0020" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0075">Variables</span><p id="par0050" class="elsevierStylePara elsevierViewall">Data collected included demographics (age, sex, history of drug use, background of psychiatric disorders) and clinical characteristics (referral history, years since diagnosis, previous unsuccessful treatment, and degree of liver fibrosis). The degree of liver fibrosis of retrieved patients was determined by elastography (Fibroscan®) and classified according to the METAVIR scale.<a class="elsevierStyleCrossRef" href="#bib0190"><span class="elsevierStyleSup">15</span></a> Patients with advanced fibrosis or cirrhosis were classified according to the criteria of Ziol et al. (2005),<a class="elsevierStyleCrossRef" href="#bib0195"><span class="elsevierStyleSup">16</span></a> and staging was completed with abdominal ultrasound. The degree of fibrosis for patients in prisons was determined with serological markers using the fibrosis index based on four factors (FIB-4) alone.<a class="elsevierStyleCrossRef" href="#bib0200"><span class="elsevierStyleSup">17</span></a> Once in consultation, patients received care in accordance with current clinical practice, and a survey was conducted to determine the reasons for non-treatment and loss to follow-up.</p></span><span id="sec0025" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0080">Statistical analysis</span><p id="par0055" class="elsevierStylePara elsevierViewall">The descriptive analysis was performed using means and standard deviations for quantitative variables following a normal distribution, while median and interquartile ranges were used for those not following a normal distribution. For categorical variables, proportions with confidence intervals were used.</p></span><span id="sec0030" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0085">Ethical considerations</span><p id="par0060" class="elsevierStylePara elsevierViewall">The study was approved by the Research Ethics Committee of Pontevedra-Vigo-Ourense on 8 October 2020 (registration code 2020/047). This committee complies, both in its composition and standard operating procedures, with current Spanish and European legislation.</p></span></span><span id="sec0035" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0090">Results</span><span id="sec0040" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0095">Patient identification</span><p id="par0065" class="elsevierStylePara elsevierViewall">Initially, a total of 1832 patients with anti-HCV antibodies and HCV RNA-positive tests were identified. Using artificial intelligence software algorithms, we were able to reduce this number to 459 untreated patients (25.1%) by excluding those that were receiving treatment at our hospital. We then proceeded to manually review their clinical history to rule out patients who were cured, in active follow-up, referred to other health areas, discontinued from treatment after the introduction of DAAs in 2017, coinfected with HIV, or deceased (<a class="elsevierStyleCrossRef" href="#fig0005">Fig. 1</a>). This led to the identification of 114 non-cured patients who were lost to medical follow-up between 2007 and 2019. Of this group, 15 patients coinfected with HIV were referred to the infectious diseases’ unit. Finally, a total of 99 patients (21.6%) with chronic HCV infection were identified as lost to medical follow-up who would be candidates for DAA treatment by the gastroenterology department. We reached out to these patients but were not able contact 35 (35.4%) of them. The remaining 64 (64.6%) were retrieved for follow-up.</p><elsevierMultimedia ident="fig0005"></elsevierMultimedia></span><span id="sec0045" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0100">Demographic and clinical characteristics</span><p id="par0070" class="elsevierStylePara elsevierViewall">The demographic and clinical characteristics of the 99 patients identified as lost to medical follow-up are depicted in <a class="elsevierStyleCrossRef" href="#tbl0005">Table 1</a>. The patient profile is mostly male (68.7%) with a mean age of 55<span class="elsevierStyleHsp" style=""></span>±<span class="elsevierStyleHsp" style=""></span>10.5 years. Around two thirds of patients (65.7%) had a history of drug use. Regarding loss to medical follow-up, 21.2% were never referred by the doctor who requested the test, and the remaining 78.8% attended the first visit but were lost to follow-up during subsequent hepatology consultation. Only 13 patients (13.1%) in this subgroup had previously tried HCV treatment without achieving a cure. The mean time from HCV diagnosis to relinkage to care was over 10 years.</p><elsevierMultimedia ident="tbl0005"></elsevierMultimedia></span><span id="sec0050" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0105">Retrieval and fibrosis evaluation</span><p id="par0075" class="elsevierStylePara elsevierViewall">The 64 patients retrieved at our centre were surveyed to enquire why they had previously discontinued medical follow-up (<a class="elsevierStyleCrossRef" href="#fig0010">Fig. 2</a>). The first cause was fear of the possible adverse effects of DAA treatment (30%), followed by mobility impediments (21%). Some patients (13%) reported a lack of perception of the disease, while 15% attributed the failure to attend follow-up to forgetfulness and confusion about the treatment. Finally, 19% reported lack of referral. When analysing the degree of liver fibrosis of these patients (<a class="elsevierStyleCrossRef" href="#tbl0005">Table 1</a>), 60.9% were at stage F0–F1, 6.3% at stage F2, 9.4% at stage F3, and 23.4% at advanced stage F4. Only 2 of the 23 patients (8.7%) with psychiatric histories were successfully recovered to offer them an antiviral treatment.</p><elsevierMultimedia ident="fig0010"></elsevierMultimedia></span><span id="sec0055" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0110">Treatment outcomes</span><p id="par0080" class="elsevierStylePara elsevierViewall">Among the 64 patients retrieved, 62 (96.9%) began DAA treatment and 54 (87.1%) achieved a sustained virological response. Two patients (3.1%) refuse the treatment. Eight patients (14.8%) were lost to follow-up during the treatment period.</p></span></span><span id="sec0060" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0115">Discussion</span><p id="par0085" class="elsevierStylePara elsevierViewall">Our active search for chronically infected HCV patients resulted in the identification of 114 non-cured patients who were lost to medical follow-up between 2007 and 2019. The strategy of using artificial intelligence to relink individuals to the health system was not only effective in detecting active infections and providing adequate follow-up, including DAA therapy, but also efficient in reducing the workload of reviewing clinical documentation by humans. Of the 99 candidates for treatment at the gastroenterology department (i.e., those with no HIV coinfection), 64 patients (64.6%) were retrieved and started treatment, most of them (87.1%) achieving SVR (by intention-to-treat analysis), reaching 100% when we take into account the 54 patients for whom we have adequate follow-up up to 12 weeks post-treatment completion. The remaining 35 patients (35.4%) were not retrieved because we could not contact them, suggesting that future efforts to recover patients lost to follow-up could benefit from the support of other areas. No differences were found between the group of retrieved patients and the group of non-retrieved patients regarding the characteristics listed in <a class="elsevierStyleCrossRef" href="#tbl0005">Table 1</a>. To our knowledge, this project is the first HCV retrieval effort ever conducted in Galicia.</p><p id="par0090" class="elsevierStylePara elsevierViewall">In our study, the use of the AI-assisted approach significantly contributed to obtain a high engagement rate (64%) which was considerably higher than the reported by other engagement activities of approximately 30%,<a class="elsevierStyleCrossRefs" href="#bib0160"><span class="elsevierStyleSup">9,10</span></a> despite some Spanish studies have reported recovery rates as high as 45%.<a class="elsevierStyleCrossRef" href="#bib0175"><span class="elsevierStyleSup">12</span></a> These results can be explained by at least two factors. The first one is that the COVID-19 pandemic resulted in a thorough update of the contact data for all individuals served by the Galician Health Service, which undoubtedly facilitated the recovery process. Secondly, the use of an AI tool in the process of finding and retrieving chronic HCV patients lost to follow-up. By fully integrating and automating the screening process of patient records, AI eliminated possible human errors and captured all necessary information about patients. As such, healthcare personnel could spend more time and efforts on outreach and engagement with patients rather than spending much time reviewing data manually. Furthermore, the large data processing efficiency of the AI could easily identify prospective patients and ensure early and accurate intervention. Therefore, it appears that incorporating AI technology has a great potential for effectively guiding patient re-engagement and augmenting the effectiveness of interventions in chronic disease management.</p><p id="par0095" class="elsevierStylePara elsevierViewall">When analysing the reasons for loss to follow-up, 58% were attributable to fear of possible adverse effects, lack of perception of the disease, or forgetfulness/confusion about the treatment. As described in previous studies,<a class="elsevierStyleCrossRef" href="#bib0205"><span class="elsevierStyleSup">18</span></a> our data suggest that educational initiatives to raise awareness about HCV infection severity and treatment possibilities among the population at risk could help reduce the number of people lost to follow-up. We also observed that over 20% of the patients were never referred to a specialist doctor post-diagnosis. The lack of referral could be due to multiple factors, such as the lack of effective HCV treatments in the past. However, HCV awareness campaigns should also aim to provide more information to healthcare professionals to guarantee referral when they see a patient who is a candidate for DAA treatment.<a class="elsevierStyleCrossRef" href="#bib0205"><span class="elsevierStyleSup">18</span></a></p><p id="par0100" class="elsevierStylePara elsevierViewall">Early HCV diagnosis, followed by treatment with current DAA therapy, is essential to achieve SVR and prevent patient progression to more severe stages of the disease.<a class="elsevierStyleCrossRef" href="#bib0210"><span class="elsevierStyleSup">19</span></a> These stages are frequently characterised by liver complications, such as cirrhosis and hepatocarcinoma (HCC), leading to a potential need for liver transplant and risk of death.<a class="elsevierStyleCrossRef" href="#bib0215"><span class="elsevierStyleSup">20</span></a> In our group of retrieved patients, almost one in three presented advanced liver fibrosis (F3) or cirrhosis (F4) at evaluation. This could be most probably explained by the long period since diagnosis, which was over ten years on average. Pursuing treatment for all HCV patients is therefore crucial to avoid the poor prognosis associated with advanced stages of the disease.<a class="elsevierStyleCrossRef" href="#bib0220"><span class="elsevierStyleSup">21</span></a> On the other hand, the high rate of treatment initiation (96.88%) and SVR achievement (100% in all patients who attended the analytical control at 12 weeks after the completion of the treatment) among the recovered patients underscores the effectiveness of using artificial intelligence to identify and re-engage lost patients and highlights the importance of offering antiviral treatment to maximise the chances of curing HCV. It is noteworthy that, despite the high rate of recovery, some patients in this category exhibit a significant rate of dropout from follow-up, even after initiating treatment (8 out of 62 patients in our case). While we lack the treatment outcomes for these 8 individuals, providing them with the necessary medication to complete the entire duration of each treatment suggests that many may have achieved SVR.<a class="elsevierStyleCrossRef" href="#bib0175"><span class="elsevierStyleSup">12</span></a></p><p id="par0105" class="elsevierStylePara elsevierViewall">The sanitary restrictions set up in 2020 to reduce SARS-CoV-2 transmission were a barrier to WHO HCV elimination goals, since they resulted in the suspension of many hepatitis screening and linkage-to-care programmes. According to recent calculations by Blach et al. (2021),<a class="elsevierStyleCrossRef" href="#bib0225"><span class="elsevierStyleSup">22</span></a> the approximate one-year hiatus in HCV screening, diagnosis and treatment could translate to an increase of up to 44,800 cases of HCC and 72,300 deaths from liver disease worldwide. In Spain, a mathematical simulation was also carried out to calculate the possible impact of the COVID-19 pandemic on HCV elimination in this country.<a class="elsevierStyleCrossRef" href="#bib0230"><span class="elsevierStyleSup">23</span></a> A cohort of 15,859 patients was compared in two different scenarios: a non-COVID-19 scenario assuming the customary diagnosis and treatment of HCV, and another COVID-19 scenario with a delay of 18 months (March 2020–June 2021). The comparison showed an increase in the number of deaths from HCC and HCV-decompensated cirrhosis of 117 and 118, respectively. The loss of HCV follow-up during the COVID-19 pandemic would reinforce the need to carry out projects to recapture lost patients.</p><p id="par0110" class="elsevierStylePara elsevierViewall">Our study has some limitations that must be acknowledged. Our findings were restricted to one health area. Therefore, the outcomes discussed here may not be applicable to other regions or countries with different sociodemographic or epidemiological features, or with alternative health system structures. There are also some limitations intrinsic to retrospective studies using administrative databases. Some information on the study population may be missing or incorrectly recorded due to possible inaccurate coding or possible variations in medical practice among professionals. Lastly, we restricted our search to patients with confirmed HCV infection, as indicated by positive antibody and RNA test result records. Our methodology therefore did not account for an unidentified number of patients with positive antibody test results who were tested before the implementation of reflex or single-step diagnosis at our centre in 2017, and who have therefore not undergone confirmatory RNA testing. Further research is required to address the needs of these patients.</p><p id="par0115" class="elsevierStylePara elsevierViewall">In conclusion, by analyzing the big data from the different digital systems that integrate the electronic medical record, we show that artificial intelligence can identify and retrieve HCV patients who were lost medical follow-up more quickly and efficiently than the manual and costly review of human resources that involves the usual searches of positive cases in isolated databases. This strategy is beneficial from the individual's perspective, since achieving SVR by providing early DAA treatment minimises the risk of developing liver cirrhosis and HCC at a later stage. It is noteworthy that the recruitment dates of our study were limited to a period (2007–2019) before the advent of the COVID-19 pandemic. Nowadays, the attention of health systems should shift back to HCV elimination programmes to identify and retrieve patients who may have been lost to medical follow-up during the COVID-19 pandemic. From an epidemiological point of view, reducing the HCV reservoir in the population helps the advance towards the goals established by the WHO to eliminate the virus by 2030.</p></span><span id="sec0065" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0120">Funding</span><p id="par0120" class="elsevierStylePara elsevierViewall">We received funding from the <span class="elsevierStyleGrantSponsor" id="gs1">Gilead Sciences FOCUS programme</span> to support viral hepatitis screening and linkage to the first medical appointment after diagnosis. FOCUS funding does not support activities beyond the first medical appointment and is agnostic as to how organisations approach subsequent patient clinical management. We received an economic award from the Foundation of the College of Physicians of Pontevedra.</p></span><span id="sec0070" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0125">Conflicts of interest</span><p id="par0125" class="elsevierStylePara elsevierViewall">Alba Carrodeguas and José Luis Gonzalez-Sánchez own stock in and are employees of Gilead Sciences. The remaining authors declare no conflicts of interest associated with the research, authorship, and publication of this article. Data collection and management were conducted independently, with additional oversight from independent data monitoring agencies.</p></span><span id="sec0075" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0130">Data sharing statement</span><p id="par0130" class="elsevierStylePara elsevierViewall">The data that support the findings of this study are available on request from the corresponding author. Data are not publicly available due to privacy or ethical restrictions.</p></span></span>" "textoCompletoSecciones" => array:1 [ "secciones" => array:14 [ 0 => array:3 [ "identificador" => "xres2225349" "titulo" => "Graphical abstract" "secciones" => array:1 [ 0 => array:1 [ "identificador" => "abst0005" ] ] ] 1 => array:3 [ "identificador" => "xres2225348" "titulo" => "Abstract" "secciones" => array:3 [ 0 => array:2 [ "identificador" => "abst0010" "titulo" => "Objective" ] 1 => array:2 [ "identificador" => "abst0015" "titulo" => "Patients and methods" ] 2 => array:2 [ "identificador" => "abst0020" "titulo" => "Results and conclusions" ] ] ] 2 => array:2 [ "identificador" => "xpalclavsec1863684" "titulo" => "Keywords" ] 3 => array:3 [ "identificador" => "xres2225350" "titulo" => "Resumen" "secciones" => array:3 [ 0 => array:2 [ "identificador" => "abst0025" "titulo" => "Objetivo" ] 1 => array:2 [ "identificador" => "abst0030" "titulo" => "Pacientes y métodos" ] 2 => array:2 [ "identificador" => "abst0035" "titulo" => "Resultados y conclusiones" ] ] ] 4 => array:2 [ "identificador" => "xpalclavsec1863683" "titulo" => "Palabras clave" ] 5 => array:2 [ "identificador" => "sec0005" "titulo" => "Introduction" ] 6 => array:3 [ "identificador" => "sec0010" "titulo" => "Material and methods" "secciones" => array:4 [ 0 => array:2 [ "identificador" => "sec0015" "titulo" => "Study design, patient identification and retrieval" ] 1 => array:2 [ "identificador" => "sec0020" "titulo" => "Variables" ] 2 => array:2 [ "identificador" => "sec0025" "titulo" => "Statistical analysis" ] 3 => array:2 [ "identificador" => "sec0030" "titulo" => "Ethical considerations" ] ] ] 7 => array:3 [ "identificador" => "sec0035" "titulo" => "Results" "secciones" => array:4 [ 0 => array:2 [ "identificador" => "sec0040" "titulo" => "Patient identification" ] 1 => array:2 [ "identificador" => "sec0045" "titulo" => "Demographic and clinical characteristics" ] 2 => array:2 [ "identificador" => "sec0050" "titulo" => "Retrieval and fibrosis evaluation" ] 3 => array:2 [ "identificador" => "sec0055" "titulo" => "Treatment outcomes" ] ] ] 8 => array:2 [ "identificador" => "sec0060" "titulo" => "Discussion" ] 9 => array:2 [ "identificador" => "sec0065" "titulo" => "Funding" ] 10 => array:2 [ "identificador" => "sec0070" "titulo" => "Conflicts of interest" ] 11 => array:2 [ "identificador" => "sec0075" "titulo" => "Data sharing statement" ] 12 => array:2 [ "identificador" => "xack767135" "titulo" => "Acknowledgements" ] 13 => array:1 [ "titulo" => "References" ] ] ] "pdfFichero" => "main.pdf" "tienePdf" => true "fechaRecibido" => "2024-05-07" "fechaAceptado" => "2024-06-21" "PalabrasClave" => array:2 [ "en" => array:1 [ 0 => array:4 [ "clase" => "keyword" "titulo" => "Keywords" "identificador" => "xpalclavsec1863684" "palabras" => array:6 [ 0 => "Chronic hepatitis C" 1 => "HCV" 2 => "Patient retrieval" 3 => "Artificial intelligence" 4 => "Direct-acting antivirals" 5 => "Liver fibrosis" ] ] ] "es" => array:1 [ 0 => array:4 [ "clase" => "keyword" "titulo" => "Palabras clave" "identificador" => "xpalclavsec1863683" "palabras" => array:6 [ 0 => "Hepatitis C" 1 => "VHC" 2 => "Recuperación de pacientes" 3 => "Inteligencia artificial" 4 => "Antivirales de acción directa" 5 => "Fibrosis hepática" ] ] ] ] "tieneResumen" => true "resumen" => array:2 [ "en" => array:3 [ "titulo" => "Abstract" "resumen" => "<span id="abst0010" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0015">Objective</span><p id="spar0010" class="elsevierStyleSimplePara elsevierViewall">Direct-acting antivirals (DAAs) to treat hepatitis C virus (HCV) infection offer an opportunity to eliminate the disease. This study aimed to identify and relink to care HCV patients previously lost to medical follow-up in the health area of Pontevedra and O Salnés (Spain) using an artificial intelligence-assisted system.</p></span> <span id="abst0015" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0020">Patients and methods</span><p id="spar0015" class="elsevierStyleSimplePara elsevierViewall">Active retrospective search of previously diagnosed HCV cases recorded in the Galician Health Service proprietary health information exchange database using the Herramientas para la EXplotación de la INformación (HEXIN) application.</p></span> <span id="abst0020" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0025">Results and conclusions</span><p id="spar0020" class="elsevierStyleSimplePara elsevierViewall">Out of 99 lost patients identified, 64 (64.6%) were retrieved. Of these, 62 (96.88%) initiated DAA treatment and 54 patients (87.1%) achieved a sustained virological response. Mean time from HCV diagnosis was over 10 years. Main reasons for loss to follow-up were fear of possible adverse effects of treatment (30%) and mobility impediments (21%). Among the retrieved patients, almost one in three presented advanced liver fibrosis (F3) or cirrhosis (F4) at evaluation. In sum, HCV patients lost to follow-up can be retrieved by screening past laboratory records. This strategy promotes the achievement of HCV elimination goals.</p></span>" "secciones" => array:3 [ 0 => array:2 [ "identificador" => "abst0010" "titulo" => "Objective" ] 1 => array:2 [ "identificador" => "abst0015" "titulo" => "Patients and methods" ] 2 => array:2 [ "identificador" => "abst0020" "titulo" => "Results and conclusions" ] ] ] "es" => array:3 [ "titulo" => "Resumen" "resumen" => "<span id="abst0025" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0035">Objetivo</span><p id="spar0025" class="elsevierStyleSimplePara elsevierViewall">Los antivirales de acción directa (AAD) representan una oportunidad para erradicar el virus de la hepatitis C (VHC). Este estudio se centró en identificar y revincular al sistema sanitario a pacientes con VHC que habían perdido previamente el seguimiento médico en el área sanitaria de Pontevedra y O Salnés (España), utilizando un sistema asistido por inteligencia artificial.</p></span> <span id="abst0030" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0040">Pacientes y métodos</span><p id="spar0030" class="elsevierStyleSimplePara elsevierViewall">Se realizó una búsqueda retrospectiva activa de casos diagnosticados de VHC en las bases de datos del Servicio Gallego de Salud, empleando la aplicación de inteligencia artificial Herramientas para la Explotación de la Información (HEXIN).</p></span> <span id="abst0035" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0045">Resultados y conclusiones</span><p id="spar0035" class="elsevierStyleSimplePara elsevierViewall">De los 99 pacientes identificados como perdidos, se logró recuperar a 64 (64,6%). De estos, 62 (96,88%) comenzaron tratamiento con AAD y 54 (87,1%) alcanzaron una respuesta virológica sostenida. El tiempo promedio desde el diagnóstico de VHC fue superior a 10 años. Las principales causas de interrupción del seguimiento fueron el temor a efectos adversos del tratamiento (30%) y dificultades de desplazamiento (21%). Casi un tercio de los pacientes recuperados presentaban fibrosis hepática avanzada (F3) o cirrosis (F4) en el momento de la evaluación. En conclusión, es posible recuperar a los pacientes con VHC perdidos en el seguimiento mediante el análisis retrospectivo de registros de laboratorio, lo cual es fundamental para alcanzar los objetivos de eliminación de la enfermedad.</p></span>" "secciones" => array:3 [ 0 => array:2 [ "identificador" => "abst0025" "titulo" => "Objetivo" ] 1 => array:2 [ "identificador" => "abst0030" "titulo" => "Pacientes y métodos" ] 2 => array:2 [ "identificador" => "abst0035" "titulo" => "Resultados y conclusiones" ] ] ] ] "NotaPie" => array:1 [ 0 => array:3 [ "etiqueta" => "◊" "nota" => "<p class="elsevierStyleNotepara" id="npar0010">These authors contributed equally to this work and share first authorship.</p>" "identificador" => "fn0005" ] ] "multimedia" => array:4 [ 0 => array:7 [ "identificador" => "fig0005" "etiqueta" => "Figure 1" "tipo" => "MULTIMEDIAFIGURA" "mostrarFloat" => true "mostrarDisplay" => false "figura" => array:1 [ 0 => array:4 [ "imagen" => "gr1.jpeg" "Alto" => 4167 "Ancho" => 1526 "Tamanyo" => 470067 ] ] "descripcion" => array:1 [ "en" => "<p id="spar0040" class="elsevierStyleSimplePara elsevierViewall">Patients who met study inclusion criteria and outcome of the analysis. DAA: direct-acting antiviral; HCV: hepatitis C virus.</p>" ] ] 1 => array:7 [ "identificador" => "fig0010" "etiqueta" => "Figure 2" "tipo" => "MULTIMEDIAFIGURA" "mostrarFloat" => true "mostrarDisplay" => false "figura" => array:1 [ 0 => array:4 [ "imagen" => "gr2.jpeg" "Alto" => 1018 "Ancho" => 1625 "Tamanyo" => 108254 ] ] "descripcion" => array:1 [ "en" => "<p id="spar0045" class="elsevierStyleSimplePara elsevierViewall">Reasons attributed in the survey for previous loss of medical follow-up among patients retrieved for clinical care at our centre.</p>" ] ] 2 => array:8 [ "identificador" => "tbl0005" "etiqueta" => "Table 1" "tipo" => "MULTIMEDIATABLA" "mostrarFloat" => true "mostrarDisplay" => false "detalles" => array:1 [ 0 => array:3 [ "identificador" => "at1" "detalle" => "Table " "rol" => "short" ] ] "tabla" => array:3 [ "leyenda" => "<p id="spar0055" class="elsevierStyleSimplePara elsevierViewall">HCV: hepatitis C virus; SD: standard deviation.</p>" "tablatextoimagen" => array:1 [ 0 => array:2 [ "tabla" => array:1 [ 0 => """ <table border="0" frame="\n \t\t\t\t\tvoid\n \t\t\t\t" class=""><tbody title="tbody"><tr title="table-row"><td class="td-with-role" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t"><span class="elsevierStyleItalic">Chronically infected HCV patients lost to follow-up, n (%)</span> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="char" valign="\n \t\t\t\t\ttop\n \t\t\t\t">99 (100%) \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t"><span class="elsevierStyleHsp" style=""></span>Sex (male), <span class="elsevierStyleItalic">n</span> (%) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="char" valign="\n \t\t\t\t\ttop\n \t\t\t\t">68 (68.7%) \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t"><span class="elsevierStyleHsp" style=""></span>Age (years), mean<span class="elsevierStyleHsp" style=""></span>±<span class="elsevierStyleHsp" style=""></span>SD \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="char" valign="\n \t\t\t\t\ttop\n \t\t\t\t">55<span class="elsevierStyleHsp" style=""></span>±<span class="elsevierStyleHsp" style=""></span>10.5 \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t"><span class="elsevierStyleHsp" style=""></span>History of drug use, <span class="elsevierStyleItalic">n</span> (%) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="char" valign="\n \t\t\t\t\ttop\n \t\t\t\t">65 (65.7%) \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t"><span class="elsevierStyleHsp" style=""></span>Background of psychiatric disorders, <span class="elsevierStyleItalic">n</span> (%) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="char" valign="\n \t\t\t\t\ttop\n \t\t\t\t">23 (23.2%) \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t"><span class="elsevierStyleHsp" style=""></span>Never referred to care, <span class="elsevierStyleItalic">n</span> (%) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="char" valign="\n \t\t\t\t\ttop\n \t\t\t\t">21 (21.2%) \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t"><span class="elsevierStyleHsp" style=""></span>Loss of follow-up, <span class="elsevierStyleItalic">n</span> (%) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="char" valign="\n \t\t\t\t\ttop\n \t\t\t\t">78 (78.8%) \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t"><span class="elsevierStyleHsp" style=""></span>Years from diagnosis, mean<span class="elsevierStyleHsp" style=""></span>±<span class="elsevierStyleHsp" style=""></span>SD \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="char" valign="\n \t\t\t\t\ttop\n \t\t\t\t">10.3<span class="elsevierStyleHsp" style=""></span>±<span class="elsevierStyleHsp" style=""></span>6.3 \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t"><span class="elsevierStyleHsp" style=""></span>Previous unsuccessful treatment<a class="elsevierStyleCrossRef" href="#tblfn0005"><span class="elsevierStyleSup">a</span></a>, <span class="elsevierStyleItalic">n</span> (%) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">13 (13.1%) \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " colspan="2" align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t"><span class="elsevierStyleVsp" style="height:0.5px"></span></td></tr><tr title="table-row"><td class="td-with-role" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t"><span class="elsevierStyleItalic">Evaluation of fibrosis, n (%)</span> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="char" valign="\n \t\t\t\t\ttop\n \t\t\t\t">64 (100%) \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t"><span class="elsevierStyleHsp" style=""></span>F0–F1 (<8.8<span class="elsevierStyleHsp" style=""></span>kPa) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="char" valign="\n \t\t\t\t\ttop\n \t\t\t\t">39 (60.9%) \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t"><span class="elsevierStyleHsp" style=""></span>F2 (8.8–9.5<span class="elsevierStyleHsp" style=""></span>kPa) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="char" valign="\n \t\t\t\t\ttop\n \t\t\t\t">4 (6.3%) \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t"><span class="elsevierStyleHsp" style=""></span>F3 (9.6–14.5<span class="elsevierStyleHsp" style=""></span>kPa) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="char" valign="\n \t\t\t\t\ttop\n \t\t\t\t">6 (9.4%) \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t"><span class="elsevierStyleHsp" style=""></span>F4 (>14.5<span class="elsevierStyleHsp" style=""></span>kPa) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="char" valign="\n \t\t\t\t\ttop\n \t\t\t\t">15 (23.4%) \t\t\t\t\t\t\n \t\t\t\t</td></tr></tbody></table> """ ] "imagenFichero" => array:1 [ 0 => "xTab3626829.png" ] ] ] "notaPie" => array:1 [ 0 => array:3 [ "identificador" => "tblfn0005" "etiqueta" => "a" "nota" => "<p class="elsevierStyleNotepara" id="npar0005">Both DAA and previous therapies.</p>" ] ] ] "descripcion" => array:1 [ "en" => "<p id="spar0050" class="elsevierStyleSimplePara elsevierViewall">Demographic characteristics of patients with chronic HCV patients lost to medical follow-up.</p>" ] ] 3 => array:5 [ "identificador" => "fig0015" "tipo" => "MULTIMEDIAFIGURA" "mostrarFloat" => false "mostrarDisplay" => true "figura" => array:1 [ 0 => array:4 [ "imagen" => "fx1.jpeg" "Alto" => 725 "Ancho" => 1333 "Tamanyo" => 136239 ] ] ] ] "bibliografia" => array:2 [ "titulo" => "References" "seccion" => array:1 [ 0 => array:2 [ "identificador" => "bibs0015" "bibliografiaReferencia" => array:23 [ 0 => array:3 [ "identificador" => "bib0120" "etiqueta" => "1" "referencia" => array:1 [ 0 => array:1 [ "referenciaCompleta" => "WHO. Global progress report on HIV, viral hepatitis and sexually transmitted infections; 2021. <a target="_blank" href="https://www.who.int/publications/i/item/9789240027077">https://www.who.int/publications/i/item/9789240027077</a> [accessed 24.01.23]." ] ] ] 1 => array:3 [ "identificador" => "bib0125" "etiqueta" => "2" "referencia" => array:1 [ 0 => array:1 [ "referenciaCompleta" => "WHO. Interim guidance for country validation of viral hepatitis elimination; 2021. <a target="_blank" href="https://www.who.int/publications/i/item/9789240028395">https://www.who.int/publications/i/item/9789240028395</a> [accessed 24.01.23]." ] ] ] 2 => array:3 [ "identificador" => "bib0130" "etiqueta" => "3" "referencia" => array:1 [ 0 => array:1 [ "referenciaCompleta" => "Ministerio de Sanidad Servicios Sociales e Igualdad. Strategic Plan for Tackling Hepatitis C in the Spanish National Health System; 2015. <a target="_blank" href="https://www.sanidad.gob.es/ciudadanos/enfLesiones/enfTransmisibles/hepatitisC/PlanEstrategicoHEPATITISC/docs/PEAHC_eng.pdf">https://www.sanidad.gob.es/ciudadanos/enfLesiones/enfTransmisibles/hepatitisC/PlanEstrategicoHEPATITISC/docs/PEAHC_eng.pdf</a> [accessed 04.01.23]." ] ] ] 3 => array:3 [ "identificador" => "bib0135" "etiqueta" => "4" "referencia" => array:1 [ 0 => array:1 [ "referenciaCompleta" => "Grupo de trabajo del estudio de prevalencia de la infección por hepatitis C en población general en España; 2017–2018. Resultados del 2° Estudio de Seroprevalencia en España (2017–2018); 2019. <a target="_blank" href="https://www.sanidad.gob.es/ciudadanos/enfLesiones/enfTransmisibles/sida/docs/INFORME_INFECCION_VHC_ESPANA2019.pdf">https://www.sanidad.gob.es/ciudadanos/enfLesiones/enfTransmisibles/sida/docs/INFORME_INFECCION_VHC_ESPANA2019.pdf</a> [accessed 04.01.23]." ] ] ] 4 => array:3 [ "identificador" => "bib0140" "etiqueta" => "5" "referencia" => array:1 [ 0 => array:1 [ "referenciaCompleta" => "Grupo técnico de cribado de la infección por el VHC. Guía de cribado de la infección por el VHC; 2020. <a target="_blank" href="https://www.sanidad.gob.es/ciudadanos/enfLesiones/enfTransmisibles/sida/docs/GUIA_DE_CRIBADO_DE_LA_INFECCION_POR_EL_VHC_2020.pdf">https://www.sanidad.gob.es/ciudadanos/enfLesiones/enfTransmisibles/sida/docs/GUIA_DE_CRIBADO_DE_LA_INFECCION_POR_EL_VHC_2020.pdf</a> [accessed 05.01.23]." ] ] ] 5 => array:3 [ "identificador" => "bib0145" "etiqueta" => "6" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Elimination of hepatitis C. Positioning document of the Spanish Association for the Study of the Liver (AEEH)" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "J. Crespo" 1 => "A. Albillos" 2 => "M. Buti" 3 => "J.L. Calleja" 4 => "J. Garcia-Samaniego" 5 => "M. Hernández-Guerra" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.17235/reed.2019.6700/2019" "Revista" => array:6 [ "tituloSerie" => "Rev Esp Enferm Dig" "fecha" => "2019" "volumen" => "111" "paginaInicial" => "862" "paginaFinal" => "873" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/31657609" "web" => "Medline" ] ] ] ] ] ] ] ] 6 => array:3 [ "identificador" => "bib0150" "etiqueta" => "7" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Loss to follow-up in the hepatitis C care cascade: a substantial problem but opportunity for micro-elimination" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:2 [ 0 => "M. van Dijk" 1 => "J.P.H. Drenth" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1111/jvh.13399" "Revista" => array:7 [ "tituloSerie" => "J Viral Hepat" "fecha" => "2020" "volumen" => "27" "paginaInicial" => "1270" "paginaFinal" => "1283" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/32964615" "web" => "Medline" ] ] "itemHostRev" => array:3 [ "pii" => "S1472648310602325" "estado" => "S300" "issn" => "14726483" ] ] ] ] ] ] ] 7 => array:3 [ "identificador" => "bib0155" "etiqueta" => "8" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Retrieval of chronic hepatitis C patients. A manifesto for action to eliminate hepatitis C in the Netherlands: the CELINE project" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "M. van Dijk" 1 => "P.A.M. Kracht" 2 => "J.E. Arends" 3 => "H. Blokzijl" 4 => "D.M. Burger" 5 => "K.J. van Erpecum" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:7 [ "tituloSerie" => "Neth J Med" "fecha" => "2019" "volumen" => "77" "paginaInicial" => "131" "paginaFinal" => "138" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/31502544" "web" => "Medline" ] ] "itemHostRev" => array:3 [ "pii" => "S0015028210022156" "estado" => "S300" "issn" => "00150282" ] ] ] ] ] ] ] 8 => array:3 [ "identificador" => "bib0160" "etiqueta" => "9" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Retrieval and re-evaluation of previously diagnosed chronic hepatitis C infections lost to medical follow-up in the Netherlands" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "J. Heil" 1 => "K. Soufidi" 2 => "F. Stals" 3 => "H. Frantzen" 4 => "A. Robroek-Schaecken" 5 => "C.M. Bakker" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1097/meg.0000000000001593" "Revista" => array:7 [ "tituloSerie" => "Eur J Gastroenterol Hepatol" "fecha" => "2020" "volumen" => "32" "paginaInicial" => "851" "paginaFinal" => "856" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/31688310" "web" => "Medline" ] ] "itemHostRev" => array:3 [ "pii" => "S1472648319307564" "estado" => "S300" "issn" => "14726483" ] ] ] ] ] ] ] 9 => array:3 [ "identificador" => "bib0165" "etiqueta" => "10" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "REtrieval And cure of Chronic Hepatitis C (REACH): results of micro-elimination in the Utrecht province" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "P.A.M. Kracht" 1 => "J.E. Arends" 2 => "K.J. van Erpecum" 3 => "S.F.T. Thijsen" 4 => "B.J.M. Vlaminckx" 5 => "A.J.L. Weersink" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1111/liv.13959" "Revista" => array:7 [ "tituloSerie" => "Liver Int" "fecha" => "2019" "volumen" => "39" "paginaInicial" => "455" "paginaFinal" => "462" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/30204289" "web" => "Medline" ] ] "itemHostRev" => array:3 [ "pii" => "S1472648313000709" "estado" => "S300" "issn" => "14726483" ] ] ] ] ] ] ] 10 => array:3 [ "identificador" => "bib0170" "etiqueta" => "11" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Recapture of patients with an incomplete diagnosis of hepatitis C virus infection" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "C. Burgui" 1 => "C. Martín" 2 => "R. Juanbeltz" 3 => "R. San Miguel" 4 => "I. Martínez-Baz" 5 => "J.M. Zozaya" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.17235/reed.2020.6944/2020" "Revista" => array:6 [ "tituloSerie" => "Rev Esp Enferm Dig" "fecha" => "2020" "volumen" => "112" "paginaInicial" => "525" "paginaFinal" => "531" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/32515981" "web" => "Medline" ] ] ] ] ] ] ] ] 11 => array:3 [ "identificador" => "bib0175" "etiqueta" => "12" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "HCV microelimination strategies: an interventional study in diagnosed patients without access to the system" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "M.F. Guerra Veloz" 1 => "P. Del Pino Bellido" 2 => "P. Cordero Ruiz" 3 => "F. Vega Rodriguez" 4 => "F. Bellido Muñoz" 5 => "E. Ramirez de Arellano" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1111/liv.14824" "Revista" => array:6 [ "tituloSerie" => "Liver Int" "fecha" => "2021" "volumen" => "41" "paginaInicial" => "928" "paginaFinal" => "933" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/33587789" "web" => "Medline" ] ] ] ] ] ] ] ] 12 => array:3 [ "identificador" => "bib0180" "etiqueta" => "13" "referencia" => array:1 [ 0 => array:1 [ "referenciaCompleta" => "Turnes Vázquez J, Cruz Ferro E, Mirás Carballal S, Zubizarreta Alberdi R, Cea Pereira L, Malvar Pintos A, et al. Estrategia para la eliminación de la hepatitis C como problema de salud pública en Galicia. <a target="_blank" href="https://www.sergas.es/Saude-publica/Documents/6927/Estrategia_eliminacion_hepatitis_C_en%20Galicia_cast.pdf">https://www.sergas.es/Saude-publica/Documents/6927/Estrategia_eliminacion_hepatitis_C_en%20Galicia_cast.pdf</a> [accessed 24.01.23]." ] ] ] 13 => array:3 [ "identificador" => "bib0185" "etiqueta" => "14" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Search for anti-hepatitis C virus positive patients lost in the health system: analysis of the absence of referring and the abandonment of the patient" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "E. Martinez-Crespo" 1 => "F. Espinosa" 2 => "A. Lue" 3 => "R.B. Ruesca" 4 => "S.L. Perez" 5 => "E.S. Villacampa" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:5 [ "tituloSerie" => "J Hepatol" "fecha" => "2017" "volumen" => "1" "paginaInicial" => "S278" "itemHostRev" => array:3 [ "pii" => "S0015028211025143" "estado" => "S300" "issn" => "00150282" ] ] ] ] ] ] ] 14 => array:3 [ "identificador" => "bib0190" "etiqueta" => "15" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "An algorithm for the grading of activity in chronic hepatitis C. The METAVIR Cooperative Study Group" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:2 [ 0 => "P. Bedossa" 1 => "T. Poynard" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1002/hep.510240201" "Revista" => array:7 [ "tituloSerie" => "Hepatology" "fecha" => "1996" "volumen" => "24" "paginaInicial" => "289" "paginaFinal" => "293" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/8690394" "web" => "Medline" ] ] "itemHostRev" => array:3 [ "pii" => "S1472648310600697" "estado" => "S300" "issn" => "14726483" ] ] ] ] ] ] ] 15 => array:3 [ "identificador" => "bib0195" "etiqueta" => "16" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Noninvasive assessment of liver fibrosis by measurement of stiffness in patients with chronic hepatitis C" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "M. Ziol" 1 => "A. Handra-Luca" 2 => "A. Kettaneh" 3 => "C. Christidis" 4 => "F. Mal" 5 => "F. Kazemi" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1002/hep.20506" "Revista" => array:6 [ "tituloSerie" => "Hepatology" "fecha" => "2005" "volumen" => "41" "paginaInicial" => "48" "paginaFinal" => "54" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/15690481" "web" => "Medline" ] ] ] ] ] ] ] ] 16 => array:3 [ "identificador" => "bib0200" "etiqueta" => "17" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Fibrosis index based on 4 factors (FIB-4) predicts liver cirrhosis and hepatocellular carcinoma in chronic hepatitis C virus (HCV) patients" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:3 [ 0 => "X. Li" 1 => "H. Xu" 2 => "P. Gao" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.12659/msm.918784" "Revista" => array:6 [ "tituloSerie" => "Med Sci Monit" "fecha" => "2019" "volumen" => "25" "paginaInicial" => "7243" "paginaFinal" => "7250" "itemHostRev" => array:3 [ "pii" => "S1472648312004099" "estado" => "S300" "issn" => "14726483" ] ] ] ] ] ] ] 17 => array:3 [ "identificador" => "bib0205" "etiqueta" => "18" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Interventions to enhance testing, linkage to care, and treatment initiation for hepatitis C virus infection: a systematic review and meta-analysis" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "E.B. Cunningham" 1 => "A. Wheeler" 2 => "B. Hajarizadeh" 3 => "C.E. French" 4 => "R. Roche" 5 => "A.D. Marshall" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1016/s2468-1253(21)00471-4" "Revista" => array:7 [ "tituloSerie" => "Lancet Gastroenterol Hepatol" "fecha" => "2022" "volumen" => "7" "paginaInicial" => "426" "paginaFinal" => "445" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/35303490" "web" => "Medline" ] ] "itemHostRev" => array:3 [ "pii" => "S0015028210027366" "estado" => "S300" "issn" => "00150282" ] ] ] ] ] ] ] 18 => array:3 [ "identificador" => "bib0210" "etiqueta" => "19" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Long-term changes on health-related quality of life in patients with chronic hepatitis C after viral clearance with direct-acting antiviral agents" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "S. Goñi Esarte" 1 => "R. Juanbeltz" 2 => "I. Martínez-Baz" 3 => "J. Castilla" 4 => "R. San Miguel" 5 => "J.I. Herrero" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.17235/reed.2019.6063/2018" "Revista" => array:7 [ "tituloSerie" => "Rev Esp Enferm Dig" "fecha" => "2019" "volumen" => "111" "paginaInicial" => "445" "paginaFinal" => "452" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/31066286" "web" => "Medline" ] ] "itemHostRev" => array:3 [ "pii" => "S1472648315005386" "estado" => "S300" "issn" => "14726483" ] ] ] ] ] ] ] 19 => array:3 [ "identificador" => "bib0215" "etiqueta" => "20" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Estimating progression to cirrhosis in chronic hepatitis C virus infection" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "A.J. Freeman" 1 => "G.J. Dore" 2 => "M.G. Law" 3 => "M. Thorpe" 4 => "J. Von Overbeck" 5 => "A.R. Lloyd" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1053/jhep.2001.27831" "Revista" => array:7 [ "tituloSerie" => "Hepatology" "fecha" => "2001" "volumen" => "34" "paginaInicial" => "809" "paginaFinal" => "816" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/11584380" "web" => "Medline" ] ] "itemHostRev" => array:3 [ "pii" => "S147264831300463X" "estado" => "S300" "issn" => "14726483" ] ] ] ] ] ] ] 20 => array:3 [ "identificador" => "bib0220" "etiqueta" => "21" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Hepatitis C elimination: a public health perspective" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:3 [ 0 => "R.K. Dhiman" 1 => "G.S. Grover" 2 => "M. Premkumar" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1007/s11938-019-00240-7" "Revista" => array:5 [ "tituloSerie" => "Curr Treat Opt Gastroenterol" "fecha" => "2019" "volumen" => "17" "paginaInicial" => "367" "paginaFinal" => "377" ] ] ] ] ] ] 21 => array:3 [ "identificador" => "bib0225" "etiqueta" => "22" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Impact of COVID-19 on global HCV elimination efforts" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "S. Blach" 1 => "L.A. Kondili" 2 => "A. Aghemo" 3 => "Z. Cai" 4 => "E. Dugan" 5 => "C. Estes" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1016/j.jhep.2020.07.042" "Revista" => array:7 [ "tituloSerie" => "J Hepatol" "fecha" => "2021" "volumen" => "74" "paginaInicial" => "31" "paginaFinal" => "36" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/32777322" "web" => "Medline" ] ] "itemHostRev" => array:3 [ "pii" => "S001502820403119X" "estado" => "S300" "issn" => "00150282" ] ] ] ] ] ] ] 22 => array:3 [ "identificador" => "bib0230" "etiqueta" => "23" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Impact of the COVID-19 pandemic on HCV elimination in Spain" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:3 [ 0 => "M. Buti" 1 => "R. Domínguez-Hernández" 2 => "M.A. Casado" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1016/j.jhep.2020.12.018" "Revista" => array:6 [ "tituloSerie" => "J Hepatol" "fecha" => "2021" "volumen" => "74" "paginaInicial" => "1246" "paginaFinal" => "1248" "itemHostRev" => array:3 [ "pii" => "S1472648317303073" "estado" => "S300" "issn" => "14726483" ] ] ] ] ] ] ] ] ] ] ] "agradecimientos" => array:1 [ 0 => array:4 [ "identificador" => "xack767135" "titulo" => "Acknowledgements" "texto" => "<p id="par0135" class="elsevierStylePara elsevierViewall">The authors thank the staff of the health area of Pontevedra and O Salnés for their contribution to this work. We also thank Anchel González Barriga and Vanessa Marfil Vives of Medical Statistics Consulting (Spain) for providing editorial support, in the form of medical writing and assembling tables based on authors’ detailed directions, collating author comments, copyediting, fact-checking, and referencing.</p>" "vista" => "all" ] ] ] "idiomaDefecto" => "en" "url" => "/02105705/unassign/S0210570524002085/v2_202408161124/en/main.assets" "Apartado" => null "PDF" => "https://static.elsevier.es/multimedia/02105705/unassign/S0210570524002085/v2_202408161124/en/main.pdf?idApp=UINPBA00004N&text.app=https://www.elsevier.es/" "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S0210570524002085?idApp=UINPBA00004N" ]
| Year/Month | Html | Total | |
|---|---|---|---|
| 2024 November | 22 | 3 | 25 |
| 2024 October | 115 | 43 | 158 |
| 2024 September | 155 | 32 | 187 |
| 2024 August | 128 | 38 | 166 |
| 2024 July | 137 | 44 | 181 |
